[A thirteen-week oral repeated dose toxicity study of suplatast tosilate (IPD-1151T) in rats]. 1992

S Nakano, and T Hayashi, and K Irimura, and A Maruden, and K Nakagawa, and K Morita
Drug Safety Laboratory, Taiho Pharmaceutical Co., Ltd., Tokushima, Japan.

A 13-week oral repeated dose toxicity study of Suplatast tosilate (IPD-1151T), a new anti-allergic agent, as well as a 5-week recovery study were carried out at dose levels of 0 (control), 200, 600, 1800 and 5400 mg/kg/day using male and female rats. The results were as follows: 1. In general conditions, salivation were observed in some rats of both sexes given 1800 mg/kg/day. Both sexes given 5400 mg/kg/day disclosed salivation and soft stool and then died after showing ataxic gait, hyperesthesia and convulsion of legs. 2. Inhibition of body weight gain in both sexes given 5400 mg/kg/day were observed from the early stage of the treatment period. 3. The food consumption was decreased from about 3-week and the water consumption was increased from the initiation of study to about 3-week in both sexes given 5400 mg/kg/day. However, both of them were remarkably decreased prior to death. 4. Fecal examination for occult blood showed an increasing tendency in the incidence of positive findings in both sexes given 1800 mg/kg/day. 5. Hematological examination showed slight decreases in erythrocytic parameters in both sexes given 1800 mg/kg/day. In both sexes given 5400 mg/kg/day hemoconcentration was observed, some animals showing decreases in leucocyte and lymphocyte counts and lymphocyte percentage. 6. Biochemical examination showed increases in total and free cholesterol levels in males given 600 mg/kg/day or more, an increased cholinesterase and decreased levels of triglyceride and cholesterol ester ratio in males given 1800 mg/kg/day. An increase in LDH was observed in both sexes given 5400 mg/kg/day and half of these animals also showed increases in GOT and Urea N. 7. The absolute weights of the pituitary, brain, thymus, heart, lungs and kidneys were increased. However, no histopathological lesion was observed in these organs. As treatment-related histological changes, atrophy in the thymus and spleen, dilation in digestive tracts, neuronal necrosis and necrotic foci in the central nervous system, necrosis of lymphocytes in the lymphoid organs and a decrease in bone marrow cell were observed in both sexes given 5400 mg/kg/day. 8. After a 5-week recovery period, above-mentioned changes had disappeared. 9. From the above results, the non-effective dose level was estimated to be 200 mg/kg/day in males and 600 mg/kg/day in females, and toxic dose level 1800-5400 mg/kg/day in both sexes.

UI MeSH Term Description Entries
D008297 Male Males
D011919 Rats, Inbred Strains Genetically identical individuals developed from brother and sister matings which have been carried out for twenty or more generations or by parent x offspring matings carried out with certain restrictions. This also includes animals with a long history of closed colony breeding. August Rats,Inbred Rat Strains,Inbred Strain of Rat,Inbred Strain of Rats,Inbred Strains of Rats,Rat, Inbred Strain,August Rat,Inbred Rat Strain,Inbred Strain Rat,Inbred Strain Rats,Inbred Strains Rat,Inbred Strains Rats,Rat Inbred Strain,Rat Inbred Strains,Rat Strain, Inbred,Rat Strains, Inbred,Rat, August,Rat, Inbred Strains,Rats Inbred Strain,Rats Inbred Strains,Rats, August,Rats, Inbred Strain,Strain Rat, Inbred,Strain Rats, Inbred,Strain, Inbred Rat,Strains, Inbred Rat
D004334 Drug Administration Schedule Time schedule for administration of a drug in order to achieve optimum effectiveness and convenience. Administration Schedule, Drug,Administration Schedules, Drug,Drug Administration Schedules,Schedule, Drug Administration,Schedules, Drug Administration
D004353 Drug Evaluation, Preclinical Preclinical testing of drugs in experimental animals or in vitro for their biological and toxic effects and potential clinical applications. Drug Screening,Evaluation Studies, Drug, Pre-Clinical,Drug Evaluation Studies, Preclinical,Drug Evaluations, Preclinical,Evaluation Studies, Drug, Preclinical,Evaluation, Preclinical Drug,Evaluations, Preclinical Drug,Medicinal Plants Testing, Preclinical,Preclinical Drug Evaluation,Preclinical Drug Evaluations,Drug Screenings,Screening, Drug,Screenings, Drug
D005260 Female Females
D006633 Histamine Antagonists Drugs that bind to but do not activate histamine receptors, thereby blocking the actions of histamine or histamine agonists. Classical antihistaminics block the histamine H1 receptors only. Antihistamine,Antihistamines,Histamine Antagonist,Antagonist, Histamine,Antagonists, Histamine
D000284 Administration, Oral The giving of drugs, chemicals, or other substances by mouth. Drug Administration, Oral,Administration, Oral Drug,Oral Administration,Oral Drug Administration,Administrations, Oral,Administrations, Oral Drug,Drug Administrations, Oral,Oral Administrations,Oral Drug Administrations
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D001190 Arylsulfonates Organic sulfonic acid esters or salts which contain an aromatic hydrocarbon radical. Aryl Sulfonates,Sulfonates, Aryl
D013452 Sulfonium Compounds Sulfur compounds in which the sulfur atom is attached to three organic radicals and an electronegative element or radical. Sulfine Compounds,Compounds, Sulfine,Compounds, Sulfonium

Related Publications

S Nakano, and T Hayashi, and K Irimura, and A Maruden, and K Nakagawa, and K Morita
May 1992, The Journal of toxicological sciences,
S Nakano, and T Hayashi, and K Irimura, and A Maruden, and K Nakagawa, and K Morita
May 1992, The Journal of toxicological sciences,
S Nakano, and T Hayashi, and K Irimura, and A Maruden, and K Nakagawa, and K Morita
May 1992, The Journal of toxicological sciences,
S Nakano, and T Hayashi, and K Irimura, and A Maruden, and K Nakagawa, and K Morita
May 1992, The Journal of toxicological sciences,
S Nakano, and T Hayashi, and K Irimura, and A Maruden, and K Nakagawa, and K Morita
May 1992, The Journal of toxicological sciences,
S Nakano, and T Hayashi, and K Irimura, and A Maruden, and K Nakagawa, and K Morita
May 1992, The Journal of toxicological sciences,
S Nakano, and T Hayashi, and K Irimura, and A Maruden, and K Nakagawa, and K Morita
May 1992, The Journal of toxicological sciences,
S Nakano, and T Hayashi, and K Irimura, and A Maruden, and K Nakagawa, and K Morita
May 1992, The Journal of toxicological sciences,
S Nakano, and T Hayashi, and K Irimura, and A Maruden, and K Nakagawa, and K Morita
May 1992, The Journal of toxicological sciences,
S Nakano, and T Hayashi, and K Irimura, and A Maruden, and K Nakagawa, and K Morita
March 2007, The Journal of urology,
Copied contents to your clipboard!